Celgene

Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
Bristol-Myers urges shareholders in open letter to support $74 billion Celgene deal amid resistance
CNBC
Bristol-Myers Squibb
M&A
Celgene
Flag link:
Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
Bad year at Celgene? Forget about it. CEO Mark Alles nabbed a big raise as compensation gyrated to $16.2M
Endpoints
Celgene
Mark Alles
Pharma CEOs
executive pay
Flag link:
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
The Bristol-Myers–Squibb Deal May No Longer Be a Sure Thing, but It Will Still Likely Happen
Barron's
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington
Xconomy
Bristol-Myers Squibb
Celgene
M&A
Wellington
Flag link:
Celgene gets fast FDA review of Revlimid combo in lymphoma
Celgene gets fast FDA review of Revlimid combo in lymphoma
Pharmaforum
Celgene
Revlimid
FDA
Roche
Rituxan
priority review
Flag link:
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Starboard plots board coup after buying into Bristol-Myers in lead-up to Celgene buyout vote
Endpoints
Jeff Smith
Starboard
M&A
Celgene
Bristol-Myers Squibb
Flag link:
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Starboard gauges Bristol-Myers shareholder support for Celgene deal
Yahoo/Reuters
Bristol-Myers Squibb
Celgene
M&A
Starboard
shareholders
Flag link:
Celgene's Revlimid defenses withstand another challenge
Celgene's Revlimid defenses withstand another challenge
Biopharma Dive
Celgene
Revlimid
Multiple Myeloma
Dr Reddy's
patents
Flag link:
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Bristol-Myers' rumored activists 'haven't made a decision' on the company yet: Starboard CEO
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Starboard Value Is to Take Stake in Bristol-Myers Squibb
Bloomberg
Bristol-Myers Squibb
Celgene
M&A
Starboard
Jeff Smith
Flag link:
Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter
Celgene Takes A Step Closer To Its Bristol Merger With Solid Quarter
Investors Business Daily
Celgene
earnings
Flag link:
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Bristol-Myers yanked its Celgene bid days before deadline—and got a better price
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Flag link:
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
What’s BMS saying about its Celgene buy behind the scenes? This transcript tells all
Fierce Pharma
M&A
Celgene
Bristol-Myers Squibb
Flag link:
Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
Celgene rolls along with another epigenetic preclinical deal featuring a Canadian biotech
Endpoints
Celgene
epigentics
Triphase Accelerator
Flag link:
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Bristol-Myers Squibb's Q4 Earnings Update Shows Why It Needs Celgene
Motley Fool
Bristol-Myers Squibb
earnings
M&A
Celgene
Flag link:
BMS talks up Celgene merger to divert Opdivo disappointment
BMS talks up Celgene merger to divert Opdivo disappointment
Fierce Pharma
Bristol-Myers Squibb
Celgene
Opdivo
Yervoy
Flag link:
A flashy 2019 start to pharma M&A, but will it last?
A flashy 2019 start to pharma M&A, but will it last?
Biopharma Dive
M&A
Celgene
Bristol-Myers Squibb
Eli Lilly
Loxo Oncology
Flag link:
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Celgene, sold for $74 billion, leaves a legacy of chutzpah in science and drug pricing
Stat
Celgene
drug pricing
M&A
Bristol-Myers Squibb
Flag link:
3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
Celgene strikes Obsidian deal to boost CAR-T options
Celgene strikes Obsidian deal to boost CAR-T options
Fierce Biotech
Celgene
Obsidian Therapeutics
CAR-T
Flag link:

Pages